Morningstar Rating

Fund Research and Analysis

by Katie Rushkewicz
Changes are afoot at Morgan Stanley Institutional US Mid Cap Value.

On Oct. 19, Morgan Stanley announced it was selling the retail arm of its asset-management business to Invesco IVZ so that it can focus on the institutional space. Once the deal closes, which is expected in mid-2010, this fund and its counterpart, Van Kampen American Value MSAVX, will fall under Invesco.  Read more 

Kudos

Consistent strategy.
Low expenses.
Decent track record. Read more 

Risks

Burgeoning asset base across all the funds run by this team may become difficult to manage.
Morgan Stanley's retail business was recently sold to Invesco, and there are still unanswered questions about how the transition will work. Read more 

Strategy

The fund's management team holds a compact portfolio of beaten-down companies with catalysts for change. The managers are willing to hold on to winners and to make significant sector bets. In general, the team is more value-oriented than former management had been, and it attempts to beat the Russell Midcap Value Index.  Read more 

Management

Jim Gilligan, the longtime lead manager of this fund's management team, stepped down on Jan. 1, 2009. Tom Copper, who has been on the team since 2003, took over as lead manager for the mid-cap strategy. John Mazanec, formerly of Wasatch Small Cap Value WMCVX, joined in mid-2008 and supplements Copper's efforts here.  Read more 

Inside Scoop

The fund's management team has a successful track record keeping a compact portfolio of undervalued and underearning companies with catalysts for improvement. There are some unanswered questions about the fund's future given Invesco's recent purchase of Morgan Stanley's retail business, but as long as the management team remains in place, which seems likely, there's less cause for concern.  Read more 

First Name
Last Name
Email Address
Zip Code
Create Password
Verify Password
(6-15 characters; case sensitive)

Picking Positions in Health Care 
Watch more 

View all of our analyst reports with a free trial to Morningstar.com Premium.